Alto Neuroscience Review Establishes Neuroplasticity as Core Mechanism in Psychiatric Disorders — Alto Neuroscience, Inc.

Event summary

Alto Neuroscience published a review in the American Journal of Psychiatry on February 3, 2026, establishing neuroplasticity as a core driver of psychiatric diseases and treatments.
The review was co-authored by Alto’s leadership team and Husseini Manji, former global head of therapeutics at Janssen.
The article highlights the lack of translatable biomarkers for plasticity changes in humans, a gap Alto aims to address with its precision psychiatry platform.
Alto’s Precision Psychiatry Platform uses EEG activity, neurocognitive assessments, and wearable data to identify patients likely to respond to its treatments.

The big picture

The review underscores the growing recognition of neuroplasticity as a unifying biological mechanism across multiple psychiatric disorders, positioning Alto at the forefront of precision psychiatry. The absence of translatable biomarkers remains a critical industry gap, and Alto’s ability to address this could differentiate its platform in a competitive market.

What we're watching

Biomarker Development: How Alto’s progress in developing translatable biomarkers for neuroplasticity will impact its clinical success rates.
Clinical Pipeline: The pace at which Alto advances its clinical-stage pipeline across bipolar depression, major depressive disorder, and schizophrenia.
Industry Leadership: Whether Alto can sustain its leadership position in biomarker-driven psychiatric drug development amid competition.